Ampio Pharmaceuticals (OTCPK:AMPE) - Stock Price, News & Analysis

AMPE Stock Overview

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States.

About the company

AMPE fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Risk Analysis

Does not have a meaningful market cap ($325K)

Highly volatile share price over the past 3 months

Earnings have declined by 28.4% per year over past 5 years

Makes less than USD$1m in revenue ($0)

+ 1 more risk

Ampio Pharmaceuticals, Inc. Competitors

Kid Castle Educational

OTCPK:KDCE

US$357.2k

MJ Holdings

OTCPK:MJNE

US$370.6k

Stem Holdings

OTCPK:STMH

US$577.3k

Item 9 Labs

OTCPK:INLB

US$70.2k

Price History & Performance

Summary of all time highs, changes and price drops for Ampio Pharmaceuticals
Historical stock prices
Current Share Price	US$0.35
52 Week High	US$8.30
52 Week Low	US$0.14
Beta	1.95
1 Month Change	-79.17%
3 Month Change	-78.40%
1 Year Change	-91.58%
3 Year Change	-99.94%
5 Year Change	-99.80%
Change since IPO	-99.94%

Recent updates

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Feb 17

Shareholder Returns

	AMPE	US Pharmaceuticals	US Market
7D	40.0%	0.08%	1.2%
1Y	-91.6%	13.2%	24.9%

Return vs Industry: AMPE underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.

Return vs Market: AMPE underperformed the US Market which returned 24.7% over the past year.

Price Volatility

Is AMPE's price volatile compared to industry and market?
AMPE volatility
AMPE Average Weekly Movement	42.1%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: AMPE's share price has been volatile over the past 3 months.

Volatility Over Time: AMPE's weekly volatility (42%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	6	Mike Martino	ampiopharma.com

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Ampio Pharmaceuticals, Inc. Fundamentals Summary

How do Ampio Pharmaceuticals's earnings and revenue compare to its market cap?
AMPE fundamental statistics
Market cap	US$324.71k
Earnings (TTM)	-US$8.63m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is AMPE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AMPE income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$8.63m
Earnings	-US$8.63m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-7.60
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	5.3%

How did AMPE perform over the long term?

See historical performance and comparison

AMPE Stock Overview

Rewards

Risk Analysis

Ampio Pharmaceuticals, Inc. Competitors

OTCPK:KDCE

US$357.2k

OTCPK:MJNE

US$370.6k

OTCPK:STMH

US$577.3k

OTCPK:INLB

US$70.2k

Price History & Performance

Recent News & Updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Price target decreased to US$3.50

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Chief Operating Officer exercised options and sold US$111k worth of stock

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

CFO, Corporate Secretary & Treasurer exercised options and sold US$56k worth of stock

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

CFO, Corporate Secretary & Treasurer exercised options to buy US$59k worth of stock.

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

New 90-day high: US$2.76

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: US$1.17

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - US$0.80

Shareholder Returns

Price Volatility

About the Company

Ampio Pharmaceuticals, Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue